Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program

Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program

STUART, Fla.--(BUSINESS WIRE)--Oct 9, 2026-

Stuart Therapeutics Submits FDA Amendment to Evaluate ST-100 in Corneal Wound Healing

Key Takeaways Stuart Therapeutics submitted an IND amendment to the FDA to investigate ST-100 (vezocolmitide) in corneal wound healing, marking the investigational therapy's first proposed expansion beyond dry eye disease The company plans a proof-of-concept study followed by a phase 2 trial in the second half of 2027 evaluating ST-100 in corneal wounds caused by trauma, surgery, ulcers, and chemical burns Stuart Therapeutics announced tha…